Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update. Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...

Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):285-289. In the adult population, eosinophilic esophagitis tends to be chronic, but stable, with no significant effect on morbidity or mortality.

Eosinophilic esophagitis is now an established cause of dysphagia. Gastroenterologists should have a high clinical suspicion for this condition if the characteristic clinical and endoscopic ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) ...

Executive Vice President, Head of Research and Development, Sanofi “Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing standard of care ...